58487-95-9Relevant articles and documents
S1P3 RECEPTOR ANTAGONIST
-
Page/Page column 17, (2008/12/06)
The present invention relates to a medicine, and more particularly to novel arylamidrazone derivatives having an antagonistic action against S1P3 receptors and a medicine containing thereof as an active ingredient. The present invention provides an arylamidrazone derivative represented by' the following formula (1) or a pharmaceutically acceptable salt thereof: wherein R1 represents a C2-C8 alkyl group which maybe substituted, a phenyl group which maybe substituted, an aromatic heterocyclic group which may be substituted, a C2-C8 alkoxy group which may be substituted, or -NR4R5 (wherein R4 and R5, which are identical or different, each represent a hydrogen atom or a lower alkyl group which may be substituted, or R4 and R5 may be joined with the adjacent nitrogen atom to form a nitrogen-containing heterocyclic ring which may be substituted); R2 and R3, which are identical or different, each represent a hydrogen atom, a halogen atom, a halo-lower alkyl group, a lower alkyl group, a lower alkynyl group, a lower alkoxy group, a cyano group, a lower alkanoyl group or a lower alkylsulfonyl group; A represents a benzene ring or a heterocyclic ring; D represents a single bond or methylene; m represents an integer from 1 to 3, and n represents an integer from 1 to 5 (with the proviso that the case where R1 is an ethoxy group, R2 is a 2,4-dichloro group, R3 is a hydrogen atom, A is a benzene ring, and D is methylene; and the case where R1 is an ethoxy group, R2 is a 2,4-dichloro group, R3 is a hydrogen atom, a 2-methyl group, a 4-methyl group, a 4-methoxy group or a 4-ethoxy group, A is a benzene ring, and D is a single bond, are excluded).
